BioTime, Inc.

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

237 documents for BioTime, Inc.

- BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors.
ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTX) and BioTime's subsidiary, OncoCyte Corporation, today announced they have each appointed Dr. Andrew ...
- Business Wire
- November 29, 2011
- BioTime, Inc. Announces Completion of ES Cell International Pte Ltd Acquisition.
Acquisition to Accelerate Development of Research and Therapeutic Products ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTIM), a biotechnology compa...
- Business Wire
- May 03, 2010
- BioTime, Inc. Awarded $733,000 in Grants Under Qualifying Therapeutic Discovery Project Program.
- Funding advances BioTime's therapeutic programs - ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTX) announced today that it has been awarded three...
- Business Wire
- November 03, 2010

- Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd.
To Develop and Market OpRegen(TM) for the Treatment of Age-Related Macular Degeneration JERUSALEM & ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex:BTIM...
- Business Wire
- October 11, 2010
- BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines.
ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTX) today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make ...
- Business Wire
- November 29, 2010
- BioTime, Inc. Announces Agreement to Acquire ES Cell International.
Acquisition to Accelerate BioTime's Development of Human Stem Cell-Based Therapeutics ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex:BTIM), a biotechno...
- Business Wire
- April 29, 2010
- BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders.
$4 Million Equity Financing Company Plans Near-Term Commercialization of iPS Cell Banking Services that Reverse the Developmental Aging of Human Cell...
- Business Wire
- January 03, 2011
- BioTime, Inc. to Form Asian Subsidiary.
Enters Into Agreements With Dr. Lu Daopei and Nanshan Memorial Medical Institute Limited BEIJING & ALAMEDA, Calif. -- BioTime, Inc. (OTCBB:BTIM) ann...
- Business Wire
- September 23, 2009
- BioTime Acquires Assets of Cell Targeting, Inc.
--Proprietary technology "paints" cells with peptides to target them to diseased tissues-- ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex:BTX) today an...
- Business Wire
- January 28, 2011
- BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases.
ALAMEDA, Calif. -- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary LifeMap Sciences, Inc. has entered into a license agreement with ...
- Business Wire
- May 22, 2012